Lanean...
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...
Gorde:
| Argitaratua izan da: | Cochrane Database Syst Rev |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Ltd
2018
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/ https://ncbi.nlm.nih.gov/pubmed/30480763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|